Neurogenic hypercholesterolemia: influence of autonomic drugs.
Eleven substances capable of either augmenting or depleting the alpha- and - beta-adrenergic capacities of the autonomic nervous system were administered to rats exhibiting hypothalamic hypercholesterolemia and to normal controls. Only the beta-adrenergic blocking agents propranolol and possibly 6-OH dopamine were observed to alter (raise) the serum cholesterol concentration, and this occurred in both experimental and control animals. Neither atropine, nor the serotonin-depleting agent, rho-chlorophenylalanine, nor the serotonin-antagonist cyproheptadine, were observed to alter serum cholesterol level. Such absence of effect was also noted with metaraminol, phenoxybenzamine, isoproterenol, epinephrine, reserpine, and alpha-methyl tyrosine.
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001337:Autonomic Agents / Q000494:pharmacology*; D001341:Autonomic Nervous System / Q000187:drug effects / Q000503:physiopathology; D002784:Cholesterol / Q000097:blood; D004298:Dopamine / Q000009:adverse effects; D006937:Hypercholesterolemia / Q000097:blood / Q000139:chemically induced / Q000503:physiopathology*; D007031:Hypothalamus / Q000187:drug effects / Q000503:physiopathology*; D008297:Male; D009206:Myocardium / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D011433:Propranolol / Q000009:adverse effects; D051381:Rats
D000316:Adrenergic alpha-Agonists; D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D001337:Autonomic Agents; D002784:Cholesterol; D011433:Propranolol; D004298:Dopamine; D009638:Norepinephrine